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ABSTRACT
The cyclin D1 gene encodes the regulatory subunit of a holoenzyme that drives
cell autonomous cell cycle progression and proliferation. Herein we show cyclin D1
abundance is increased >30-fold in the stromal fibroblasts of patients with invasive
breast cancer, associated with poor outcome. Cyclin D1 transformed hTERT human
fibroblast to a cancer-associated fibroblast phenotype. Stromal fibroblast expression
of cyclin D1 (cyclin D1Stroma) in vivo, enhanced breast epithelial cancer tumor growth,
restrained apoptosis, and increased autophagy. Cyclin D1Stroma had profound effects on
the breast tumor microenvironment increasing the recruitment of F4/80+ and CD11b+
macrophages and increasing angiogenesis. Cyclin D1Stroma induced secretion of factors
that promoted expansion of stem cells (breast stem-like cells, embryonic stem cells
and bone marrow derived stem cells). Cyclin D1Stroma resulted in increased secretion
of proinflammatory cytokines (CCL2, CCL7, CCL11, CXCL1, CXCL5, CXCL9, CXCL12),
CSF (CSF1, GM-CSF1) and osteopontin (OPN) (30-fold). OPN was induced by cyclin
D1 in fibroblasts, breast epithelial cells and in the murine transgenic mammary gland
and OPN was sufficient to induce stem cell expansion. These results demonstrate that
cyclin D1Stroma drives tumor microenvironment heterocellular signaling, promoting
several key hallmarks of cancer.
www.impactjournals.com/oncotarget
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INTRODUCTION

1), GM-CSF, CCL2 and other factors which participate in
tumor progression [31].
Currently, relatively little evidence supports an
alternate model in which changes in the expression
of a target gene within the CAFs drive tumorigenesis.
Furthermore, the molecular genetic drivers governing the
CAF phenotype are not well understood. It is however
known that intratumoral hypoxia, which down regulates
caveolin-1 via lysosomal degradation [32-35], augments
the CAF phenotype [34]. Herein we show the expression
of the cyclin D1 gene is increased in human breast cancer
stroma. We show that increased expression of cyclin
D1 in stromal fibroblasts can transform it to a cancerassociated fibroblast phenotype and that stromal cyclin
D1 is sufficient to augment breast tumor epithelial cell
growth in mice. Analysis of heterotypic signals induced
by stromal cyclin D1 identified activation of heterocellular
signaling that promoted tumor inflammation, angiogenesis
and stem cell expansion.

The cyclin D1 gene encodes the regulatory subunit
of a holoenzyme that phosphorylates and inactivates the
retinoblastoma (pRb) protein, promoting G1/S phase
cell cycle entry. Cyclin D1 enhances breast cancer
cellular proliferation in vivo and endogenous cyclin D1
maintains estradiol-mediated mammary epithelial cell
gene expression in vivo [1]. The abundance of cyclin D1
is rate limiting in the growth of tumors in vivo, including
ErbB2-induced breast cancer [2, 3] and gastrointestinal
tumorigenesis [4]. In addition to canonical signaling
governing the G1/S cell-cycle transition, cyclin D1 also
participates in non canonical cell autonomous functions.
Thus cyclin D1 promotes cellular migration [5] and DNA
repair [6], governs the expression of specific miRNAs
and determines the processing of miRNA through the
induction of Dicer [7]. The ability of cyclin D1 to govern
gene transcription correlates with the recruitment of
cyclin D1 and cointegrator enzyme complexes into the
promoter regulatory region of target genes in the context
of chromatin [8, 9].
An historical view has focused on oncogenic
signaling within tumor cells that drive the hallmarks of
cancer [10]. However, solid tumors consist of both tumor
cells and stromal cells. Modification of fibroblasts in the
stroma immediately adjacent to transformed epithelial
cells has been documented in several tumor systems
[11-15]. Cancer-associated fibroblasts (CAFs) are a
preponderant stromal population in many tumor types
[16]. CAFs originate from different cell populations
including bone-marrow mesenchymal stem cells [17],
resident fibroblasts [18], cancer cells (following epithelial
to mesenchymal transition (EMT)) or endothelial cells [19,
20]. The growth characteristics of breast cancer-associated
fibroblasts are different from those of fibroblasts associated
with normal breast epithelial cells [21]. CAFs associated
with invasive breast carcinoma cells convey abnormal
migratory behavior in vitro [22] and altered expression
of growth factors such as platelet-derived growth factor,
insulin-like growth factors I and II, transforming growth
factor-β1, hepatocyte growth factor/epithelial scatter
factor, and keratinocyte growth factor [21, 23-27] and
increased expression of inflammatory genes [28].
Studies of fibroblasts in the vicinity of the
malignant lesion support a role for stromal cells in
tumorigenesis [29, 30]. In these circumstances genetic
changes in the epithelial cell compartment are considered
to be the independent drivers of the tumor inflammatory
microenvironment. Evidence suggests that oncogenic and
collaborative oncogenic signals within tumor epithelial
cells recruit inflammatory cells which alter stromal
fibroblasts to become cancer-associated fibroblasts
(CAFs). Tumor cell derived inflammatory cytokines and
growth factors including colony stimulating factor (CSF-

www.impactjournals.com/oncotarget

RESULTS
Cyclin D1 expression is increased in the stroma
of human breast cancer associated with poor
prognosis
In view of the finding that the cyclin D1 gene
encodes the regulatory subunit of the holoenzyme that
phosphorylates pRB, and RB phosphorylation is increased
in human breast cancer-associated fibroblasts [34], we
determined the abundance of cyclin D1 in the stroma
of human breast cancers. The mRNA for cyclin D1 was
increased approximately 32-fold in breast cancer (Figure
1A, 1B).
A cohort of 914 breast cancer specimens with
available clinical outcome was stained for stromal cyclin
D1 using immunofluorescence-immunohistochemistry.
Tissue Studio (Definiens) quantitative analysis was
performed on high-resolution digital images obtained
using the ScanScope FL line scanner (Leica Biosystems)
to determine levels of cyclin D1 expression specifically
within the stroma of cancer specimens. A majority of the
cyclin D1-positive cells in breast cancer stroma display
a fibroblastoid phenotype with their characteristic highly
elongated nuclei (Supplementary Figure 1A). Some
stromal cell nuclei appear round and may represent other
cell types but could also be fibroblastoid cells sectioned
transversely. For immunostaining of cyclin D1 in human
breast cancer specimens we have used clinical grade
DAKO 3642 rabbit monoclonal antibody specific for
the 36 kDa human cyclin D1. The antibody has been
validated for formalin-fixed paraffin-embedded tissue
and is widely used. As expected, the majority of cyclin
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Figure 1: Cyclin D1 is increased in the stroma of human breast cancer associated with poor outcome. A.. The relative
abundance of cyclin D1 in either the normal breast (N = 6) or breast cancer stroma (N = 53) was quantitated as mean ± SEM and
shown as either Log2 or B. relative mRNA abundance. C. Kaplan-Meier plot indicating unfavorable prognosis in breast cancer patients
with high cyclin D1 in stromal cells. Quantitative immunofluorescence and data-driven dichotomization of nuclear cyclin D1 levels in
breast cancer stromal cells is associated with increased risk of disease recurrence (N = 914, p = 0.03). D. Venn diagram of GO terms,
or E. gene expression comparing cancer-associated fibroblast (CAF) genes (breast cancer-associated fibroblasts compared with normal
mammary gland fibroblasts [34] and cyclin D1 induced genes in fibroblasts [62]). F. Relative number of fibroblasts or G. breast cancer cells
determined in co-culture of hTERT fibroblasts (control) or hTERT fibroblasts expressing cyclin D1 (cyclin D1stroma) co-incubated with the
breast cancer cell line, MDA-MB-231 (N = 7 for cyclin D1stroma and N = 12 for control at time 72 hour. N = 2 for all of other time points).
www.impactjournals.com/oncotarget
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D1 staining is in the cell nuclei (Supplementary Figure
1A). Data-driven cutpoint analysis using X-tile software
[36] identified a sub-population of patients with the
highest levels of nuclear cyclin D1 within the stromal
cell compartment (Supplementary Figure 1A) to be at a
significantly increased risk of breast cancer recurrence
(Cox Regression Hazard Ratio = 1.76 (CI: 1.20-2.57),
p = 0.004) (Figure 1C). Furthermore the stromal cyclin
D1 levels in the tumor were significantly greater than the
adjacent normal stromal cyclin D1 in the same patients
(Supplementary Figure 1B). Cancer-associated fibroblasts
(CAFs) from human breast cancers compared with normal
mammary fibroblasts isolated from patients are enriched
for gene expression associated with cellular proliferation
and pRb/E2F target genes [34]. A comparison of the GO
terms evidenced a 64% (9/14) overlap of functional terms
induced by cyclin D1 and induced in CAFs compared with
normal mammary fibroblasts (Figure 1D). A comparison
of cyclin D1-regulated genes in fibroblasts with gene
expression induced in CAFs demonstrated 20/126 (16%)
of genes were concordant (Figure 1E).
When co-cultured with breast cancer cells,
hTERT immotalizd human fibroblasts can acquire a
cancer-associated fibroblast phenotype [37]. In order
to determine the functional consequence of cyclin D1
expression in the stromal fibroblasts, cyclin D1 was
stably integrated into hTERT fibroblasts. Western blot
analysis of the hTERT cells overexpressing cyclin D1
(cyclin D1Stroma) demonstrated a 2-fold increase in cyclin
D1 abundance, which is within the physiological range
of changes in cyclin D1 abundance (Figure 1G). Breast
cancer cellular growth, and co-culture experiments were
conducted as previously described [38]. MDA-MB-231
cells were grown with hTERT fibroblasts expressing
cyclin D1 (cyclin D1Stroma) or its control GFP vector
(controlStroma). The proliferation of hTERT fibroblasts
with overexpression of cyclin D1 was increased 2-fold
(p-value = 0.011), consistent with the known role for
cyclin D1 to promote cellular proliferation (Figure 1F).
The proliferation of MDA-MB-231 cells was increased
approximately 65% at 72 hrs by cyclin D1Stroma suggesting
stromal cyclin D1 participates in heterocellular signals to
the breast cancer cells (p-value = 0.004) (Figure 1G).

vs 182.3 µM x 1003 (N = 6)) (Figure 2B, 2C). Tumors
were extirpated and analyzed for markers of proliferation,
apoptosis and cancer-associated fibroblast differentiation
(Figure 2D-2G). Ki-67, a marker of cellular proliferation,
was increased 80% by cyclin D1Stroma in the breast cancer
epithelial cells (11.7x104 vs 6.5x104, (N = 4)) (Figure
2D). Terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) staining as a measure of apoptosis
was reduced 63% in the breast cancer epithelial cells by
cyclin D1Stroma (21x104 vs 7.6x104 for N = 3) (Figure 2E).
Induction of the cancer-associated fibroblast phenotype
correlates with the expression of calponin and αSMA
[37]. The cyclin D1Stroma breast tumors showed increased
abundance of αSMA (Figure 2F, 2.6-fold, p = 0.018) and
calponin (Figure 2G).

Stromal cyclin D1 enhances autophagy, features of
the cancer-associated fibroblast, neoangiogenesis
and tumor inflammation
The tumor stroma has the capacity to induce or
restrain autophagy in the tumor epithelium [39]. In order to
determine whether stromal cyclin D1 induced autophagy
in the breast tumor we assessed known markers. LC3B,
a marker of autophagy, was induced 40% in the breast
cancer epithelial cells (12.4x104 vs 18.9x104 for N = 4)
(Figure 3A). Breast cancer epithelial cell abundance of
Beclin 1 (BCN1), a novel Bcl-2-interacting mammalian
autophagy gene [40], was induced 50% by cyclin D1Stroma
(Figure 3B). Chaperone-mediated autophagy (CMA) is
a proteolytic system that degrades intracellular proteins
in lysosomes. Lysosomal-associated membrane protein 1
(LAMP-1) (also known as lysosome-associated membrane
glycoprotein 1 and CD107a (Cluster of Differentiation
107a)), is a marker for chaperone-mediated autophagy
[41]. LAMP1 was induced 70% by cyclin D1Stroma (Figure
3C, 2.1x105 vs 3.5x105, N = 4). Collectively these studies
demonstrate that increased cyclin D1Stroma promotes breast
cancer tumor growth, associated with the induction of
cell proliferation, reduction in apoptosis and induction of
autophagy in the breast cancer epithelial cell compartment.
As a surrogate for neoangiogenesis we measured the
αvβ3 binding ECM protein von Willebrand Factor (vWF),
which was increased 4-fold by cyclin D1Stroma (Figure 3D).
Tumor-associated macrophages (TAMs) play a critical role
in the proliferation, invasion, angiogenesis, and metastasis
of human breast carcinomas [42, 43] and increased
macrophage infiltration into tumors confers metastatic
potential and poor prognosis in breast cancer [44]. We
therefore analyzed the presence of F4/80+ macrophages,
which were increased 2.5-fold by cyclin D1Stroma (Figure
3E). The CD11b+ staining macrophages, which also
contribute to breast cancer metastasis [45], were increased
3.2-fold by cyclin D1Stroma (Figure 3F).

Stromal cyclin D1 enhances tumor growth,
proliferation and reduces apoptosis
In order to examine the functional significance of an
increase in cyclin D1 expression in the tumor-associated
fibroblasts, MDA-MB-231 cells were co-injected with
hTERT fibroblasts expressing either cyclin D1 (cyclin
D1Stroma) or control GFP vector (controlStroma). Tumors were
visualized by the expression of the Luc2 gene (Figure 2A).
Tumor weight was increased 40% (0.31 vs 0.22 grams
(N = 6)), and tumor volume was increased 93% (351.5
www.impactjournals.com/oncotarget
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Figure 2: Stromal cyclin D1 expression increases breast tumor growth in mice. A. Mice were injected with either hTERT control

(controlstroma) or hTERT-cyclin D1 (cyclin D1stroma), in equal number together with MDA-MB-231 cells (RFP) and the tumor size assessed
with B. tumor weight and C. tumor volume shown as mean ± SEM for N = 6 separate animals in each group. D. Immunohistochemical
analysis of the tumors for cell proliferation (Ki-67), E. apoptosis (TUNEL), F. α-SMA and G. calponin with quantitation shown as mean ±
SEM for N = 6 separate animals in each group.
www.impactjournals.com/oncotarget
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Figure 3: Cyclin D1stroma expression increases breast cancer inflammation. A. Immunohistochemical analysis of the tumors
for A.-C. mitophagy/autophagy (LC3B, BECN-1, LAMP-1), D. angiogenesis (Von Willebrand Factor (VWF), E. F4/80+ macrophages, F.
CD11b+ macrophages, with quantitation shown as mean ± SEM for N = 6 separate animals in each group.
www.impactjournals.com/oncotarget
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Cyclin D1 conditioned medium produces proinflammatory cytokines (CCL2, CCL7, CCL11,
CXCL1, CXCL5, CXCL9, CXCL12), CSF (CSF,
G-CSF) and osteopontin (OPN)

receptors (Figure 4A). Chemokines have been grouped
into four subfamilies (CXC, CC, CX3C and C) on the
basis of a structural cysteine motif found near the amino
terminus. Comparing cyclin D1Stroma and controlStroma
demonstrated the induction of CCL8 (MCP2, 8-fold),
CCL7 (MCP3 39-fold), CXCL5 (39-fold), GM-CSF (10fold), CXCL1 (9-fold), TNFα, and TNFβ (Figure 4B). In
order to determine the role of endogenous cyclin D1 in
maintaining production of secreted factors we compared
cyclin D1-/- with cyclin D1+/+ MEFs. Endogenous cyclin

In order to determine the mechanism by which
cyclin D1Stroma promoted MDA-MB-231 tumor
inflammation and growth, we analyzed cyclin D1Stroma
secreted factors, measuring growth factors, cytokines and

Figure 4: Fibroblast cyclin D1 expression increases secretion of inflammatory cytokines. A. Soluble growth factor/cytokine/
receptor array of conditioned medium from hTERT-controlstroma or hTERT-cyclin D1stroma or C.-F., from cyclin D1+/+ or cyclin D1-/- MEFs.
Data is shown as fold change.
www.impactjournals.com/oncotarget
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D1 maintained abundance of CCL11, GM-CSF, IGFBP-6,
IL-3Rb, IL-5, XCL1 (lymphotactin), CCL2, SCF, SDF-1α,
VCAM (Figure 4C, 4D) and osteopontin (OPN), (30-fold)

(Figure 4E, 4F). Collectively these studies demonstrated
that increased cyclin D1 in fibroblasts induces the
abundance of proinflammatory cytokines and chemokines.

Figure 5: Proteome analysis of cyclin D1 conditioned medium identifies inflammatory cytokines and dendritic cell
maturation pathways. A. Venn diagram comparing the overlap of proteins in secretomes of hTERT-controlstroma and hTERT-cyclin
D1stroma cells (n = 3 for each condition). B. Hierarchical clustering heat map of hTERT-controlstroma and hTERT-cyclin D1stroma secretomes
based on LFQ intensities of identified proteins. C. Volcano plot of proteins identified in secretome analysis. Log2 ratios of LFQ intensities in
hTERT-cyclin D1stroma vs. hTERT-controlstroma were plotted against negative log10 Student’s t-test p-values. Significantly changed proteins,
defined as absolute fold-change > 2 and p < 0.05, are shown in blue. D. Canonical pathways (Ingenuity Pathway Analysis) associated with
secretome changes in hTERT-cyclin D1stroma relative to hTERT-controlstroma are shown for a significance threshold of absolute Fold-change
> 2.5 and Student’s t-test p < 0.05. Bars represent negative log10 Fisher’s exact test, right-tailed p-values for each canonical pathway. The
ratio of proteins that significantly changed relative to the total identified proteins in this dataset for each pathway is listed above each bar.
www.impactjournals.com/oncotarget
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Cyclin D1 conditioned medium proteomic analysis
identified cytokines and pathways governing
macrophage and dendritic cell maturation

CD34 is a marker of hematopoietic stem cells (HSC)
[47]. In order to examine the mechanisms governing the
induction of the CD11b+ from the hematopoietic stem
cells, the murine bone marrow cells were cultured with the
supernatant from either cyclin D1-/- or cyclin D1+/+ MEFs
(Figure 6A). We used the standard HSC protocol with
Flt3L media for 9 days and analyzed CD34 expression by
flow cytometry. The histogram representing the percentage
of CD34+ cells demonstrated that cyclin D1 conditionedsupernatant increased the percentage of CD34+ cells from
14% to 35% (Figure 6A).
In order to examined further the mechanisms by
which cyclin D1-mediated secreted factors increased the
proportion of CD11b+ cells, we investigated the potential
role of the pRB protein. Comparison was therefore made
of the secreted signals derived from cyclin D1-/-, pRB-/and cyclin D1/pRB-/- MEFs. Western blot demonstrated
loss of the cognate protein in the MEFs (Supplementary
Figure 2A), maintenance of cellular diameter and reduced
proliferation rates in the cyclin D1-/- cells (Supplementary
Figure 2B, 2C). The supernatant derived from similar
numbers of MEFs of each genotype were then used in
assays with the murine bone marrow (Supplementary
Figure 3). The CD34+ population was reduced from 35%
to 27% when incubated with cyclin D1+/+/pRB-/- media,
however the cyclin D1-/-/pRB-/- media resulted in 23%
CD34+ cells, which was greater than the proportion shown
from the supernatant of cyclin D1-/- MEFs. Together these
studies suggest that endogenous cyclin D1-mediated
secreted factors are the primary driver to expand CD34+
cells.
The increase in CD11b+ MDSC by media derived
from cyclin D1+/+ vs cyclin D1-/- MEFs is consistent with
a role for endogenous fibroblast cyclin D1 in producing
secreted factors that promote stem cell expansion.
Traditional stem cell assays were therefore conducted,
quantitating the number of embryonic stem cell colonies to
determine the possibility that cyclin D1-mediated secreted
factors promote stem cells. The supernatant was incubated
with murine ES cells, and colony number determined.
The conditioned medium from cyclin D1 expressing cells
induced both mES cell proliferation and colony number
(Figure 6B-6E).

To evaluate the extent to which cyclin D1
regulates the tumor microenvironment, we performed
an unbiased global secretome analysis of conditioned
media from cyclin D1Stroma and controlStroma hTERT cell
lines by analyzing biological triplicates for each group
(Supplementary Table 1). A total of 935 proteins were
identified by two or more peptides (final protein FDR
= 0.5%) with 924 proteins (98.8%) detected in both
groups (Figure 5A). Protein levels in the secretomes
were determined using label free quantitation. Biological
replicates were highly similar, while abundance levels of
many secreted proteins were different between the groups
(Figure 5B). At a threshold of absolute fold-change greater
than 2 and Student’s t-test p-value less than 0.05, 250
proteins (27% of identified proteins) were significantly
different between the groups (Figure 5C) with 174 proteins
upregulated and 76 downregulated in the cyclin D1Stroma
relative to controlStroma. Canonical pathways significantly
associated with cyclin D1 were primarily associated
with cytokines and immune response, including “IL6 Signaling,” “Interferon Signaling,” “Dendritic Cell
Maturation,” “Activation of IRF by Cytosolic Pattern
Recognition Receptors,” and “Th1 Pathway” (Figure 5D).
IL-6 was among the most upregulated proteins in cyclin
D1Stroma exhibiting a 7-fold increase (Supplementary Table
1). These results are consistent with a primary role for
cyclin D1-regulated secreted factors in determining tumor
cytokine signaling and the immune response. While some
cytokines, osteopontin, and other proteins assayed by
targeted approaches (Figure 4) were not identified in the
proteome analysis, these proteins were most likely present
at very low abundance levels that were below the detection
threshold of the proteomics method used here.

Cyclin D1 conditioned medium induces expansion
of CD34 positive hematopoietic stem cells (HSCs)
and differentiation of CD34 positive hematopoietic
stem cells (HSCs) into dendritic cells

Cyclin D1 induces the secretion and cleavage of
osteopontin (OPN)

CD11b+ macrophages are thought to participate in
the progression of breast tumorigenesis [46], therefore
we sought to examine further the mechanism by which
cyclin D1 in the stroma may promote the production of
CD11b+ cells. Myeloid-derived suppressor cells (MDSC)
are a heterogeneous population of cells which strongly
inhibit anti-cancer immune responses and in the mouse
are characterized by the expression of CD11b. Given the
increase in CD11b in the cyclin D1Stroma, we examined
the potential role of cyclin D1-induced fibroblast
heterocellular signals in the expansion of a CD11b+
population using murine bone marrow derived cells.
www.impactjournals.com/oncotarget

In our assessment of cyclin D1-mediated soluble
factors, OPN was induced 30-fold (Figure 4F). Elevated
levels of OPN correlate with poor prognosis in breast
cancer [48]. OPN is a soluble pleiotropic cytokine that
binds to integrin receptors, including α4β1, α9β1, and
α9β4 expressed by leukocytes, to induce cell adhesion,
migration, and survival in immune cells (neutrophils,
macrophages, T cells, mast cells, and osteoclasts [49, 50].
81762
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Figure 6: Cyclin D1 conditioned medium induces expansion of CD34 positive hematopoietic stem cells (HSCs) and
promotes differentiation of CD34 positive hematopoietic stem cells (HSCs) into dendritic cells. A. The bone marrow cells

were cultured in media derived from cyclin D1-/- or cyclin D1+/+ MEFs for 9 days and analyzed for CD34 expression by flow cytometry
as described in Materials and Methods. Histogram represents the percentage of CD34+ cells. The gate was set based on unstained and/or
isotype control for each sample. B.-C. The supernatant from cyclin D1-/- or cyclin D1+/+ MEFs were incubated with ES cells and assessed
for proliferation or D.,E. colony number. Quantitation of ES cell colony number shown as mean ± SEM for N = 3.
www.impactjournals.com/oncotarget
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Because OPN has the capacity to recapitulate many of
the cyclin D1-mediated stromal effects, further analysis
was conducted of cyclin D1 and OPN using cultured
cells and transgenic mice. Cyclin D1 reintroduction
into cyclin D1-/- MEFs induced OPN abundance (Figure
7A). OPN is cleaved into active forms by thrombin and
matrix melloproteases to form a C terminal fragment that
is chemotactic to macrophages [51-53]. A comparison of
cyclin D1-/- and cyclin D1+/+ MEF showed an increased
abundance of the OPN cleaved forms (Figure 7B). As
cleavage is conducted by matrix metalloproteases (MMP3, MMP-7) [54], we assessed the abundance of MMP by
Western blot. MMP-3 was induced 7-fold in the cyclin
D1+/+ cells (Figure 7B). This finding is consistent with
recent studies in which cyclin D1 was shown to induce
MMP gene expression in the mammary gland in vivo
[1]. OPN abundance was determined by ELISA in the
cell culture media of both of cyclin D1+/+ and cyclin D1-/MEFs. Cyclin D1 increased OPN secretion approximately
6-fold (Figure 7C). In order to determine whether cyclin
D1 induces OPN in vivo, two transgenic paradigms were
deployed. The first in which the abundance of cyclin D1
is induced through a tetracycline inducible operator in the
mammary gland of transgenic mice [9] (Figure 7D). 14
days after the induction of the cyclin D1 transgene in the
mammary gland, immunohistochemical staining showed a
6-fold induction of OPN by the cyclin D1WT (Figure 7E).
In order to determine whether endogenous cyclin
D1 maintained OPN abundance, we assessed transgenic
mice in which the cyclin D1 gene could be excised in the
adult mammary gland. The inducible cyclin D1 genetic
deletion mice (ROSA26-Cre-ERT2-cyclin D1fl/fl) [55] were
treated with tamoxifen for 5 days (Figure 7F), and after a
subsequent 28 days immunohistochemistry was conducted
for OPN. Mammary gland staining for OPN was reduced
3-fold in the cyclin D1 genetic deletion mice (Figure
7G). In order to determine whether OPN as sufficient to
induce the ES cell expansion demonstrated with cyclin
D1 conditioned medium, ES cells assays were conducted
in the presence of OPN or control. ES cell number was
induced 1.75-fold (Figure 7H, (N = 2, P 0.06).

chromogen (brightfield) stains block light and is hypoluminescent and has a signal range of only one log. In
contrast, fluorescent signals emit light and are hyperluminescent with a signal range of 2-2.5 logs. Consistent
with the functional significance of the increased cyclin
D1 in the stroma, several target proteins known to be
repressed by cyclin D1 (NRF1, mTTFA), were reduced in
the stroma (data not shown).
Breast epithelial cell cyclin D1 protein
overexpression is found in up to 50% of human breast
cancers [56]. Increased cyclin D1 gene copy number
is found in up to 20% of breast tumors suggesting
that activation of cyclin D1 can occur via additional
mechanisms, including transcriptional and posttranscriptional dysregulation. Prior studies had assessed
the prognostic significance of nuclear cyclin D1
abundance in the breast cancer epithelial cell. These prior
studies demonstrated that increased nuclear epithelial
cell cyclin D1 abundance correlates with better prognosis
[57]. In these studies cyclin D1 mRNA levels in the cyclin
D1 “high group” were induced 1.8-fold [57]. Cyclin
D1 amplification or overexpression however identified
a subset of ERα+ breast cancers with worse prognosis
[58], suggesting additional interactions modify cyclin
D1 function. As cyclin D1 has been shown to promote
cellular migration it will be of interest in future studies
to determine whether stromal cyclin D1 correlates with
increased tumor invasiveness. The current studies provide
evidence for the independent prognostic significance of
stromal cyclin D1 and suggest consideration be given to
evaluation of cyclin D1 in the stroma of breast cancer
when considering patient prognosis.
We determined the functional significance of
stromal cyclin D1 through co-injecting hTERT fibroblasts
expressing cyclin D1 (cyclin D1Stroma) or control GFP
vector (controlStroma). Cyclin D1Stroma enhanced breast
tumor volume 93%, with a 2-fold increase in breast cancer
epithelial cell proliferation and a 63% reduction in breast
tumor epithelial cell apoptosis. The finding that stromal
cyclin D1 increased tumor growth is consistent with
previous findings, in which cyclin D1 was shown to be a
marker of senescent stroma [59] and senescent stroma was
shown to stimulate tumor growth [60].
In the current co-culture studies, cyclin D1Stroma
increased cellular proliferation, consistent with
heterocellular signaling driving breast cancer tumor
growth. Many of the growth factors and chemokines
induced by cyclin D1Stroma are capable of promoting breast
cancer epithelial cell proliferation and reducing breast
cancer epithelial apoptosis. It is likely that combinatorial
interactions of the secreted signals participate in the
growth phenotype. Cyclin D1Stroma increased breast cancer
epithelial cell autophagy, increasing the abundance of
BCN1 and LAMP1. Increased tumor epithelial cell
autophagy is thought to participate in tumor cell metabolic
heterogeneity by driving epithelial cell catabolism and

DISCUSSION
The current studies demonstrate that cyclin D1
mRNA abundance is increased 30-fold in the stroma of
patients with breast cancer. A quantitative analysis of
stromal cyclin D1 protein in 914 patients demonstrated
that increased nuclear stromal fibroblast expression of
cyclin D1 predicted poor outcome. Previous publications
did not report the presence of cyclin D1 protein in breast
cancer stroma but focused on reporting the more abundant
of cyclin D1 in cancer epithelial cells. In part, this could
be due to lower sensitivity of the DAB chromogen
staining used by these older publications compared to
our immunofluorescence based staining. In general,
www.impactjournals.com/oncotarget

81764

Oncotarget

Figure 7: Cyclin D1 induces Osteopontin (OPN) abundance. A. Western blot analysis for OPN in cyclin D1-/- MEFs transduced

with either control vector or a cyclin D1 expressing vector. β-actin is a loading control. B. Western blot analysis of either wild type or cyclin
D1-/- MEFs for the abundance of OPN and its bioactive cleaved forms, MMP3 (cleavge enzyme for OPN) and β-actin loading control. C.
ELISA of OPN in cell culture media of either wild type or cyclin D1-/- MEFs. The serum-free cell cuture media were collected after 48
hours. D. Schematic representation of transgenic mice in which a cyclin D1 cDNA was induced in the mammary gland upon addition of
doxycycline. E. Immunohistochemistry for OPN in the mammary gland of transgenic mice with quantitation of IHC shown as mean +
SEM for N = 3 separate mice. F. Schematic representation of transgenic paradigm to delete cyclin D1 in mice using tamoxifen inducible
Cre expression. G. Immunohistochemistry for OPN in the mammary gland of transgenic mice with quantitation of IHC shown as mean
± SEM for N = 3 separate mice. H. Assay of OPN mediated induction of embryonic stem (ES) cells. Image of the plates in which ES cell
assays were conducted using either vehicle or OPN, with representative colonies shown at high magnification (200x). Quantitation of ES
cell colony number shown as mean ± SEM for N = 3.
www.impactjournals.com/oncotarget
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glycolysis [39]. The mammalian gene encoding Beclin1,
a novel Bcl-2-interacting mammalian autophagy gene,
can inhibit tumorigenesis and is expressed at decreased
levels in human breast carcinoma. Cell surface expression
of LAMP1 can serve as a ligand for selectins and help
mediate cell-cell adhesion correlating with increased
cancer invasiveness. The finding that the stromal cyclin D1
increases breast cancer autophagy contrasts with the cell
autonomous function of cyclin D1 in tissue mono culture,
wherein cyclin D1 restrains epithelial cells and fibroblast
autophagy via phosphorylation of LKB1[61]. Thus cyclin
D1 conveys tissue compartment specific effects, with
stromal fibroblast cyclin D1 increasing autophagy, and
epithelial cell cyclin D1 restraining autophagy.
In the current studies, cyclin D1 expression in
fibroblasts determined a gene expression profile that
overlapped with the previously described expression
pattern associated of cancer-associated fibroblasts [34,
62]. Of the 126 CAF-induced genes, 20 were also induced
by cyclin D1. Of the 14 functional terms induced in
CAFs, 9 functional terms were also induced by cyclin
D1. Cyclin D1Stroma induced an inflammatory infiltration
in the breast cancers with increased infiltration of CD11b+
macrophages. In mice, MDSCs are defined as being
CD11b+ and Gr-1+. Canonical pathways significantly
associated with cyclin D1 mediated secreted proteins
were associated with “Dendritic Cell Maturation,” and
cyclin D1 conditioned medium induced expansion of
CD34 positive hematopoietic stem cells (HSCs) and
differentiation of CD34 positive hematopoietic stem
cells (HSCs) into dendritic cells. The current studies are
consistent with a role for cyclin D1Stroma, in the induction
of stem cells. Cyclin D1-mediated heterotypic factors
increased the number of bone marrow derived stem cells
(BMDSC) and increased embryonic stem cell (ESC)
colonies 3-fold. We demonstrated that full length OPN
enhanced the number of ES colonies approximately
2-fold. Several cyclin D1-mediated secreted factors
have the capacity to differentiate MDSC, including
granulocyte macrophage-colony stimulating factor (GMCSF), macrophage-colony stimulating factor (M-CSF),
and stem cell factor (SCF) [63, 64]. Cyclin D1 induced
GM-CSF 1.75-fold and SCF 1.5-fold. We identified cyclin
D1 at the regulatory region of the Csf1 gene in ChIP-seq
(Supplementary Figure 4). As myeloid-derived suppressor
cells (MDSCs) accumulate in tumors during malignant
progression and in ex vivo CTL assays can suppress T cell
responses [65] and block DC maturation at the invasive
edge of tumors [65], the current studies suggest a novel
mechanism by which stromal cyclin D1 may augment
tumor progression.
What might be the functional significance of
the cyclin D1-stroma–mediated induction of F4/80+
macrophages ? Monocytes and/or macrophages promote
the extravasation, survival, and persistent growth of

www.impactjournals.com/oncotarget

metastatic cells [66]. The role of M1 vs M2 macrophages,
and markers used to define these populations remains
controversial. However iNOS is produced by
macrophages, and increased stromal iNOS correlated with
mammary tumor progression [67]. In the current studies
increased iNOS staining of macrophages was observed
in the cyclin D1 stroma tumors in vivo (data not shown),
consistent with a protumorigenic role of the cyclin D1
stromal-augmented tumor inflammation.
Increased expression of fibroblast cyclin D1 induced
the abundance of inflammatory chemokines/cytokines in
fibroblasts, that are known to promote tumorigenesis.
Cyclin D1 conditioned medium produced proinflammatory cytokines (CCL2, CCL7, CCL11, CXCL1,
CXCL5, CXCL9, CXCL12), CSF (CSF, G-CSF) and
osteopontin (OPN). Several of the individual components
of the secretome, induced by cyclin D1Stroma, were
previously described as tumor stroma secreted factors.
In addition to cytokines/chemokines, proteomic analysis
showed increased secretion of 176 proteins in response
to cyclin D1 expression, that correlated with functional
pathways including “IL-6 signaling”, “interferon
signaling”, and “dendritic cell maturation”. Endogenous
cyclin D1 maintained abundance of stromal cell-derived
factor 1 (SDF-1α), also called CXCL12, which plays
a central role in the promotion of tumor growth and
angiogenesis. SDF-1α stimulates carcinoma cell growth
directly through binding the CXCR4 receptor on tumor
epithelial cells and augments neoangiogenesis through
recruiting endothelial progenitor cells (EPCs) [68].
Endogenous cyclin D1 also maintained the abundance
of CCL2, which is known to enhance the retention of
metastasis-associated macrophages [69].
How might cyclin D1 induce the abundance of
inflammatory chemokines/cytokines in fibroblasts?
Cyclin D1 regulates transcription, both in cultured cells
[70] and in vivo [1, 71], through interacting in the context
of chromatin with target transcription factors [9, 72]
recruiting histone regulatory enzymes [70, 73] thereby
regulating transcription in a kinase-independent manner
[55]. Herein, cyclin D1 was recuited in the context of
chromatin to the promoter regulatory regions of several
cytokine/chemokine genes that were induced by cyclin
D1, including Csf, Cxcl1, Xcl, and Vcam1 (Supplementary
Figure 4). Therefore cyclin D1 may induce cytokine/
chemokine expression via this well established
transcriptional mechanism.
The mechanisms governing the induction of cyclin
D1 in the stroma of breast cancer patients is not known.
Genetic deletion studies have identified components of
the aberrant signaling pathway in CAFs. In recent studies
endogenous c-Myc was also shown to participate in the
development of the inflammatory stromal environment
[74]. Deletion of the JunD gene in the stroma promoted
tumor growth and metastasis, associated with increased
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ROS production, with consequent accumulation of
HIF1α and HIF1α-dependent induction of CXCL12,
activating CXCR4, promoting CAF differentiation [75].
Hypoxia-induced cancer cells derived TGFβ also drives
CAF differentiation [68, 76]. Stromal Cav-1 is frequently
degraded upon hypoxemic induced lysosomal degradation
and loss of Cav-1 is sufficient to drive the CAF genotype.
Cav-1 mediates anti-proliferative and survival function via
the cyclin D1 gene, which is transcriptionally repressed
by Cav1 [77] via a β-catenin/Tcf pathway [78]. CAF
gene expression analysis evidence increased expression
of cell-cycle pathways, increased phosphorylation of
pRB and loss of Cav1 was highly correlated with poor
response to tamoxifen therapy [34]. The possibility the
hypoxia induces degradation of Cav-1 and consequently
induces cyclin D1 in the breast cancer stroma remains to
be investigated.

Human skin fibroblasts, immortalized with
telomerase reverse transcriptase protein (hTERT-BJ-1)
were originally purchased from Clontech, Inc. and
transduced with either MSCV-cyclin D1 or MSCV-GFP as
previously described [8]. The breast cancer cell line MDAMB-231 was purchased from ATCC. The hTERT-BJ-1
and MDA-MB-231 cell lines were obtained in early 2000.
Mouse embryonic fibroblasts (MEFs) of distinct genotypes
(cyclin D1-/-, pRB-/-, cyclin D1-/-/pRB-/-) were prepared and
cultured as previously described [79]. The MEFs of cyclin
D1-/-, pRB-/-, cyclin D1-/-/pRB-/- and wildtype control were
generated in 2006 and 2011. All cells were maintained
in DMEM with 10% Fetal Bovine Serum (FBS) and
Penicillin 100 units/mL-Streptomycin 100 µg/mL. Mouse
embryonal stem (ES) cells were cultured following the
standard protocol [80]. Briefly, tissue culture plates were
coated with 0.1% (v/v) porcine gelatin (Sigma-Aldrich
Corp, St. Louis, MO) in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen) in the presence of 15% fetal
bovine serum (ES-tested Hyclone, Perbio, Logan, UT), 0.1
mM 2-β-mercaptoethanol, 0.1 mM non-essential amino
acids, 2 mM glutamine, 0.1 mM sodium pyruvate, and
1,000 units/ml murine LIF (Chemicon International Inc.,
Temecula, CA). The cell culture medium was changed
daily.
The early passage MEFs were stored in liquid
nitrogen. The cells thawed from low passage stocks were
used within one month of the initial thaw. During the
experiments, the morphology of all cell lines was routinely
checked under phase contrast microscopy. All of the newly
revived cells were treated with BM-cyclins (Roche) and
the presence of possible mycoplasma contamination was
routinely excluded with Hoechst 33258 staining under
high magnification fluorescent microscope.

MATERIALS AND METHODS
Gene expression analysis
The abundance of stromal cyclin D1 mRNA in
breast tumors was determined by Oncomine, a cancerprofiling database. A cut-off of 1.5-fold enrichment and
a p-value of <0.05 were used to interrogate the cancerprofiling database (OncomineTM Research Edition, https://
www.oncomine.org). Comparison of microarray data sets
representing cyclin D1-dependent and cancer-associated
fibroblast (CAF) upregulated genes was conducted using
published data sets [34, 62]. Statistical significance for
overlapping cyclin D1 induced and CAF-dependent
genes and Gene Ontology (GO) PANTHER terms were
calculated using the hypergeometric distance statistical
formula. The significance level for P values of gene set
overlap and GO functions was established as P<0.01.

Cell co-culture

Materials

hTERT-fibroblasts and MDA-MB-231 cells were
plated on glass coverslips in 12-well plates in 1-ml of
complete media. MDA-MB-231 cells were plated within
2 hours of fibroblast plating. The total number of cells per
well was 1 × 105. Experiments were performed at a 5:1
fibroblast-to epithelial cell ratio. As controls, monocultures
of fibroblasts and MDA-MB-231 cells were seeded using
the same number of cells as the corresponding co-cultures.
The day after plating, media was changed to DMEM with
10% NuSerum (a low protein alternative to FBS; BD
Biosciences) and Penicillin-Streptomycin. Cells were
maintained at 37°C in a humidified atmosphere containing
5% CO2.

Antibodies were directed to Ki-67 (AB16667,
Abcam), calponin (SC136987, Santa Cruz), BECN1
(sc-11427, Santa Cruz), LC3B (#3868, Cell Signaling),
LAMP1 (sc-17768, Santa Cruz), F4/80 (ab6640,
Abcam), CD11b (PA5-18727, Invitrogen), Sca1
(ab-51317, Abcam), osteopontin (ab8488, Abcam),
LC3A/B (ab58610, Abcam). Secondary antibodies for
immunofluorescence were Alexa Green 488 nm and
Alexa Orange-Red 546 nm (Invitrogen). 4,6-diamidino2-phenylindole (DAPI) (D3571), Prolong Gold Anti-fade
mounting reagent (P36930), Slow-Fade Anti-fade reagent
(S2828). Osteopontin was obtained from SIGMA (Cat. #
O2260).
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Immunocytochemistry

Medical Discovery Tower, Toronto, Canada. The cells
were maintained undisturbed at 37°C in 5% CO2 and 90%
relative humidity. On day 9, the cells were collected by
gentle trypsinization and phenotyped for marker of stem
cells (CD34) as well as myeloid (CD11c+/CD11b+/B220-)
and plasmacytoid (CD11c+/CD11b-/B220+) dendritic cell
markers, using specific antibodies for flow cytometry as
described [83].

Immunocytochemistry
was
performed
as
previously described [81]. All steps were performed at
room temperature. Briefly, after 30 minutes fixation in
2% paraformaldehyde, cells were permeabilized for 10
minutes with immunofluorescence (IF) buffer (PBS, 0.2%
BSA, 0.1% TritonX-100). Then, cells were incubated for
10 minutes with NH4Cl in PBS to quench free aldehyde
groups. Primary antibodies were incubated in IF buffer for
1 hour. After washing with IF buffer (3x, 10 minutes each),
cells were incubated for 30 minutes with fluorochromeconjugated secondary antibodies diluted in IF buffer.
Finally, slides were washed with IF buffer (3x, 10 minutes
each), incubated with the nuclear stain and mounted.

Apoptosis studies
Terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) (TACS2 TdT DAB, Trevigen)
staining was used as a measure of apoptosis in tissues
as previously described [85]. Apoptosis was quantified
by Flow Cytometry using the Annexin V-Cy5 apoptosis
detection kit, as per the manufacturer’s instructions
(Abcam).

Flow cytometric analysis
GFP+ MDA-MB-231 cells were plated in co-culture
with hTERT-fibroblasts or in mono-culture. The day
after, media was changed to DMEM with 10% NuSerum
and cells were grown for an additional 48 hours. Then,
to isolate the GFP+ MDA-MB-231 cell population, cocultured cells were sorted using a 488 nm laser. As a
critical control, mono-cultures of GFP+ MDA-MB-231
cells were sorted in parallel. For DNA content analyses,
sorted cells were fixed in 70% ethanol overnight at 4°C
and stained with PI. DNA cell content was analyzed by
flow cytometry. For proliferation analysis, cells were
incubated with BrdU (Amersham Pharmacia Biotech) for
one hour before sorting. Cells were washed in PBS, fixed
in cold 70% ethanol and flow cytometry was employed for
analysis of nascent DNA synthesis (BrdU incorporation).
Cell cycle analysis was performed using FlowJo 8.8
software. BrdU data was represented as a percentage of
the total population.

Western blotting
hTERT-vector and hTERT-cyclin D1 fibroblasts
were harvested in lysis buffer (10 mM Tris-HCl pH 7.5,
150 mM NaCl, 1% Triton X-100, 60 mM octylglucoside),
containing protease inhibitors (Roche Applied Science)
and phosphatase inhibitors (Roche Applied Science) and
centrifuged at 13,000x g for 15 min at 4°C to remove
insoluble debris. After centrifugation to remove insoluble
debris, protein concentration was determined using the
Bradford assay (BioRad). 30 µg of proteins were loaded
and separated by SDS-PAGE and transferred to a 0.2
µm nitrocellulose membrane (Fisher Scientific). After
blocking for 30 min in TBST (10 mM Tris-HCl pH
8.0, 150 mM NaCl, 0.05% Tween-20) with 5% nonfat
dry milk, membranes were incubated with the primary
antibody for 1 hour, washed and incubated for 30 min with
horseradish peroxidase-conjugated secondary antibodies.
The membranes were washed and incubated with an
enhanced chemi-luminescence substrate (ECL;Thermo
Scientific).

CD34+ hematopoietic stem cell differentiation into
bone marrow-derived dendritic cells
The effect of stromal cyclin D1-mediated secreted
factors was tested on the differentiation of CD34+
hematopoietic stem cells (HSCs) into bone-marrow
derived dendritic cells (BMDCs) as described previously
[82, 83]. Briefly, 30 x 106 BM cells were obtained from
6- to 10-week-old C57BL/6J mice (purchased from
The Jackson Laboratory, Bar Harbor, ME) cultured in
medium obtained from MEF derived from wild type,
cyclin D1-/- or pRB-/-, or cyclin D1-/-/pRB-/- animals and
supplemented with 20% of Flt3L, (Fms-related tyrosine
kinase 3 ligand), containing supernatant, produced
from an SP2/0 transfected cell line that secretes murine
recombinant Flt3L [84]. These cells were kindly provided
by Dr. Robert Rottapel, Ontario Cancer Institute, Toronto
www.impactjournals.com/oncotarget

Osteopontin ELISA
1.2 x 106 of cells in 2 ml DMEM with 10% FBS
were seeded in 12-well plate and cultured overnight
in CO2 incubator at 37oC. The media was then changed
to FBS-free DMEM media and cultured for another 48
hours. The culture media was collected and centrifuged
at 4000 rpm to remove the cell debris. OPN in cultured
media was measured by Mouse/Rat Osteopontin (OPN)
Quantikine ELISA Kit from R&D Systems based on the
manufacture’s protocol.
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Animal studies

Paraffin-embedded breast tumor tissues

The appropriate Thomas Jefferson University
institutional committee approved protocols were followed
when working with all mice. Animals were housed and
maintained in a pathogen-free environment/barrier facility
of Thomas Jefferson University under National Institutes
of Health (NIH) guidelines. Mice were kept on a 12 hours
light/dark cycle with ad libitum access to chow and water.
Approval for all animal protocols used for this study was
reviewed and approved by the Institutional Animal Care
and Use Committee. The tetracycline inducible mammary
epithelial cell targeted cyclin D1 transgenic mice (MMTVrtTA-cyclin D1WT) and the tamoxifen inducible cyclin D1
genetic deletion mice (ROSA26-Cre-ERT2-cyclin D1fl/fl)
were previously described [55].
In brief, transgenic founder lines were backcrossed
with wild type FVB mouse for three generations to
obtain the stably inherited transgene line, followed by
cross mating with MMTV-rtTA line (a kind gift from Dr.
Lewis Chodosh’s lab) to obtain cyclin D1+/+/rtTA+/+ mice.
8-week-old tetracycline-inducible cyclin D1/rtTA bitransgenic pregnant female mice (12 days postcoitus) were
administered doxycycline in the drinking water (2 mg/
ml). After 7 days of doxycycline treatment, the mice were
sacrificed and mammary glands extracted for analysis.
Conditional cyclin D1fl/fl mice were a generous gift from
Dr. Sicinski. C57BL/6J ROSA26-Cre-ERT2 mice were a
kind gift from Dr. Streamson C. Chua Jr. ROSA26-CreERT2-cyclin D1fl/fl mice were generated by crossing cyclin
D1fl/fl and ROSA26-Cre-ERT2 mice. Ccnd1 knock-out
mice were generated by a daily intra-peritoneal injection
of Tamoxifen (1 mg/200 µl) for 5 days, followed by a
wash out period of four weeks. Mammary gland tissues
were then collected. Wild type Cre-ERT2 mice were used
as control.
For breast tumor implantation studies, tumor cells
(MDA-MB-231 (GFP+; 1 × 106 cells) were mixed with
hTERT-fibroblasts (3 × 105 cells) in 100 µl of sterile PBS
and were co-injected into the flanks of athymic NCr nude
mice (NCRNU; Taconic Farms; 6–8 weeks of age). After
4 weeks, mice were sacrificed; tumors were excised and
frozen in liquid nitrogen-cooled isopentane.

Breast cancer tissue microarrays were constructed
from formalin-fixed, paraffin-embedded unselected tumor
specimens from Thomas Jefferson University Hospital
pathology archives obtained under IRB approved
protocols. Patients were diagnosed between the years 1981
and 2005 with median clinical follow-up data of 8.5 years.

Quantitative immunofluorescence
Stromal cyclin D1 was detected in clinical
breast cancer specimens by immunofluorescenceimmunohistochemistry (IF-IHC) performed on an
Autostainer Plus (Dako) as previously described [87]
with the following specifications: antigen retrieval used
the DAKO PT-module with citric acid buffer (pH 6.0) and
rabbit monoclonal cyclin D1 antibody (Dako, M3635) was
diluted 1:200 and coincubated with mouse monoclonal
anti-pancytokeratin (clone AE1/AE3, DAKO, 1:100) for
45 minutes.
Quantitative analysis of cyclin D1 was performed
as previously described [86]{Peck, 2016 #603;Peck,
2016 #230} using the ScanScope FL line scanner (Leica
Biosystems) to capture high-resolution digital images
followed by quantification of cyclin D1 levels in the
stroma of tumor specimens using Tissue Studio image
analysis software (Definiens). Briefly, user-guided
machine learning was performed to generate an analysis
solution that identified DAPI-stained cell nuclei within the
stroma of each tumor specimen. Mean nuclear cyclin D1
signal intensity was calculated for stromal cells in each
tumor core.

Cytokine arrays
Human cytokine arrays (ab133997) were obtained
from Abcam (Cambridge, MA). The medium of hTERTcontrolstroma and hTERT-cyclin D1stroma was prepared
by culturing cells in DMEM with 10% FBS for 48 hrs.
Mouse cytokine arrays were purchased from Raybiotech
(Norcross, GA). Conditioned medium of cyclin
D1+/+ and cyclin D1−/− MEFs was prepared by culturing
cells in serum free DMEM for 48 hrs. The experiments
were conducted exactly as described in the manufacture’s
protocol.

Survival studies
For statistical analysis, cyclin D1 expression in
stroma, (high vs low), was derived from data-driven
optimal cutpoint analysis using X-tile software [36, 86,
87]. Breast cancer recurrence-free survival was analyzed
using the Kaplan-Meier survival curve estimator, logrank test and Cox proportional hazards model. Nuclearlocalized cyclin D1 levels were compared in normal or
malignant tissue using t-test.
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Proteome analysis of cyclin D1 secretome
Conditioned serum-free media from hTERT-cyclin
D1 and control hTERT fibroblasts was centrifuged and
filtered through a 0.22 µm membrane to remove cell
debris and protease inhibitors were added (1 mM PMSF,
1 µg/ml leupeptin, and 1 µg/ml pepstatin. Samples were
81769

Oncotarget

Author’s contribution

concentrated on 3 KDa MWCO Amicon Ultra-4 centrifugal
filter units and membranes were washed with 1% SDS,
10 mM Tris, pH 7.4 to extract adsorbed proteins (70-fold
final concentration), followed by separation for 0.5 cm on
10% Bis-Tris NuPAGE gels (Thermo Fisher Scientific).
In-gel trypsin digestion was performed as described
previously [88] with the following changes: trypsin was
used at 4 ng/µl and digests were carried out for 4 hr at
37 °C. Digested samples were lyophilized, resuspended
in 0.1% formic acid, 4% acetonitrile immediately prior to
LC-MS/MS using a Q Exactive Plus mass spectrometer
(Thermo Fisher Scientific) as previously described [89].
Briefly, peptides were separated by reverse-phase using
a 180 µm x 20 mm nanoACQUITY UPLC Symmetry
C18 trap column and a 1.7 µm x 250 mm nanoACQUITY
UPLC Peptide BEH C18 column with 1.7 µm particles
(Waters) using a 245 min gradient. Data-dependent
analysis was performed on the 20 most abundant ions
using an isolation width of 1.5 m/z with a 30 sec dynamic
exclusion window. Peptide match was preferred, and
unassigned and single charge ions were rejected. Data
were analyzed by MaxQuant 1.5.1.2 [90] and the builtin Andromeda search engine using the UniProt human
sequence database (July 28, 2014; 145,433 sequences)
and an in-house database of common contaminants, such
as keratins, trypsin, and media components (from UniProt,
July 28, 2014; 3,671 sequences). False discovery rates
(FDR) for peptides and proteins were set to 1% for the
initial output. Matching between runs was performed with
a 0.7 min match window and 20 min alignment window.
Label-free quantitation (LFQ) was performed with a
minimum peptide ratio of 1 required for normalization.
MaxQuant results were processed using Perseus version
1.5.0.31 [91] and Microsoft Excel 2016. Contaminants
and protein groups identified by a single peptide were
removed from the dataset which reduced the protein FDR
from 1% to 0.5% in the final dataset. LFQ intensities were
log2 transformed, and missing values were imputted from
a median downshifted Gaussian distribution with a width
of 0.3 and downshift of 1.8. Hierarchical clustering was
performed on Z-scored, log2-transformed LFQ intensities
using Euclidean distance with k-means preprocessing (300
clusters). Log2 ratios were calculated as the difference
in log2 LFQ intensity averages between cyclin D1 and
control secretomes. Two-tailed, unpaired, homoscedastic
Student’s t-test calculations were performed for pairwise
comparisons because the datasets approximated normal
distributions. Fold-change values for ratios less than 1 are
represented as negative reciprocals of the ratios. Canonical
pathway analysis was performed using Ingenuity Pathway
Analysis (QIAGEN) core analysis. Proteins were mapped
to Ingenuity Knowledgebase identifiers by gene symbol.
The entire list of identified proteins was used as the
reference in statistical calculations.
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